Trials of antidiabetic drugs in amyotrophic lateral sclerosis: Proceed with caution?

Neurodegenerative Diseases

Volumn 13, Issue 4, 2014, Pages 205-208

  Jawaid, Ali ^a   Paganoni, Sabrina ^b,c,d   Hauser, Cecile ^a   Schulz, Paul E ^e  

^a University of Zurich Brain Research Institute   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; GLUCOSE; LIPID;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTROCYTE; BODY MASS; CELL COUNT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAT CONTENT; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERMETABOLISM; INFLAMMATION; INSULIN RESISTANCE; LIFESPAN; LIPID METABOLISM; METABOLIC SYNDROME X; MOTONEURON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PENTOSE PHOSPHATE CYCLE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UPREGULATION; AGONISTS; CLINICAL TRIAL (TOPIC); CELL IMMORTALIZATION; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOGLYCEMIC AGENTS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84900304623     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000353158     Document Type: Review

References (35)

1. Mackenzie IR, Rademakers R, Neumann M: TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995-1007.
2. Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, Roeber S, Kretzschmar HA, Munoz DG, Kusaka H, Yokota O, Ang LC, Bilbao J, Rademakers R, Haass C, Mackenzie IR: FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 2011; 134: 2595-2609.
3. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
4. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
5. Benatar M: Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007; 26: 1-13.
6. Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC, GERP ALS Study Group: A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One 2012; 7:e37885.
7. Shibata N, Kawaguchi-Niida M, Yamamoto T, Toi S, Hirano A, et al: Effects of the PPARγ activator pioglitazone on p38 MAP kinase and IκBα in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuropathology 2008; 28: 387-398.
8. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF: Peroxisome proliferator-activated receptor- γ agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005; 191: 331-336.
9. Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S: The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARα) and PPARγ increase Cu2+, Zn2+ superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001; 50: 3-11.
10. Ceriello A: Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008; 24: 14-26.
11. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP: Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 75-82.
12. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP: Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 2004; 101: 11159-11164.
13. Mattson MP, Cutler RG, Camandola S: Energy intake and amyotrophic lateral sclerosis. Neuromolecular Med 2007; 9: 17-20.
14. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V: Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70: 1004-1009.
15. Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC: Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011; 258: 613-617.
16. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM: Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44: 20-24.
17. Jawaid A, Murthy SB, Wilson AM, Qureshi SU, Amro MJ, Wheaton M, Simpson E, Harati Y, Strutt AM, York MK, Schulz PE: A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler 2010; 11: 542-548.
18. Jawaid A, Salamone AR, Strutt AM, Murthy SB, Wheaton M, McDowell EJ, Simpson E, Appel SH, York MK, Schulz PE: ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur J Neurol 2010; 17: 733-739.
19. Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC: Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci USA 2010; 107: 16320-16324.
20. Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, Tamori Y, Yokoi N, Watanabe M, Matsuo E, Nishimura O, Seino S: PGRN is a key adipokine mediating high fat dietinduced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 2012; 15: 38-50.
21. Levine AJ, Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
22. Newington JT, Pitts A, Chien A, Arseneault R, Schubert D, Cumming RC: Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. PLoS One 2011; 6:e19191.
23. Mergenthaler P, Kahl A, Kamitz A, van Laak V, Stohlmann K, Thomsen S, Klawitter H, Przesdzing I, Neeb L, Freyer D, Priller J, Collins TJ, Megow D, Dirnagl U, Andrews DW, Meisel A: Mitochondrial hexokinase II (HKII) and phosphoprotein enriched in astrocytes (PEA15) form a molecular switch governing cellular fate depending on the metabolic state. Proc Natl Acad Sci USA 2012; 109: 1518-1523.
24. Braithwaite SS, Palazuk B, Colca JR, Edwards CW 3rd, Hofmann C: Reduced expression of hexokinase II in insulin-resistant diabetes. Diabetes 1995; 44: 43-48.
25. Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ: Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS One 2011; 6: e24189.
26. Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, Mattson MP, Wang Y, Harvey BK, Ray B, Lahiri DK, Greig NH: Exendin- 4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012; 7:e32008.
27. Sun H, Knippenberg S, Thau N, Ragancokova D, Körner S, Huang D, Dengler R, Döhler K, Petri S: Therapeutic potential of N-acetyl-glucagon- like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 2013; 33: 347-357.
28. Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, Van den Berg LH: Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:638-642.
29. Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, Preux PM, Couratier P: Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosispatients. J Neurol Neurosurg Psychiatry 2011;82:628-634.
30. Huisman MH, de Jong SW, Verwijs MC, Schelhaas HJ, van der Kooi AJ, de Visser M, Veldink JH, van den Berg LH: Family history of neurodegenerative and vascular diseases in ALS: a population-based study. Neurology 2011;77:1363-1369.
31. Shimizu T, Nagaoka U, Nakayama Y, Kawata A, Kugimoto C, Kuroiwa Y, Kawai M, Shimohata T, Nishizawa M, Mihara B, Arahata H, Fujii N, Namba R, Ito H, Imai T, Nobukuni K, Kondo K, Ogino M, Nakajima T, Komori T: Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler 2012;13:363-366.
32. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y: Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 2012;51:1501-1508.
33. Gallo V, Wark PA, Jenab M, Pearce N, Brayne C, Vermeulen R, Andersen PM, Hallmans G, Kyrozis A, Vanacore N, Vahdaninia M, Grote V, Kaaks R, Mattiello A, Bueno-de-Mesquita HB, Peeters PH, Travis RC, Petersson J, Hansson O, Arriola L, Jimenez-Martin JM, Tjønneland A, Halkjær J, Agnoli C, Sacerdote C, Bonet C, Trichopoulou A, Gavrila D, Overvad K, Weiderpass E, Palli D, Quiros JR, Tumino R, Khaw KT, Wareham N, Barricante-Gurrea A, Fedirko V, Ferrari P, Clavel-Chapelon F, Boutron-Ruault MC, Boeing H, Vigl M, Middleton L, Riboli E, Vineis P: Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 2013;80:829-838.
34. Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, Thompson JL: Body mass index (BMI) as predictor of ALSFRSR score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:212-216.
35. O'Reilly ÉJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, Thun M, Park Y, Kolonel LN, Ascherio A: Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:205-211.